TrialCancer2016

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Phuong L Mai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.